t
Dechra Pharmaceuticals PLC's Board issued a statement on Thursday, 21 October 2021, prior to its Annual General Meeting held at 9:30 am on the same day. The company reported strong trading in the first quarter of the financial year, particularly in the US, and confirmed no other new trading updates would be made at the AGM. Dechra announced it will release its interim results for the six-month period to 31 December 2021 on 21 February 2022.
| Date | 21 Oct 2021 |
| Time | 07:00:03 |
| Category | Trading updates |
| ID | 7344P |
Thursday, 21 October 2021
Dechra® Pharmaceuticals PLC
(Dechra, Group, Company)
Annual General Meeting
Trading update
The Board of Dechra issues the following statement prior to the Annual General Meeting (AGM) which will take place at the Company's offices at 6 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA at 9.30 am today, Thursday 21 October 2021:
Trading in the first quarter of the financial year was strong, especially in the US as we continued to outperform the sector and benefit from strong growth in the Companion Animal market. Although trading is currently encouraging, it remains too early in the year to extrapolate this performance across the full year.
No other new trading updates are to be made at the AGM today.
Dechra will announce its interim results for the six month period to 31 December 2021 on 21 February 2022.
|
Enquiries: |
|
|
Dechra Pharmaceuticals PLC |
|
|
Ian Page, Chief Executive Officer |
Office: +44 (0) 1606 814 730 |
|
Paul Sandland, Chief Financial Officer e-mail: [email protected] |
Office: +44 (0) 1606 814 730
|
|
|
|
|
TooleyStreet Communications Ltd |
|
|
Fiona Tooley, Director e-mail: [email protected] |
Mobile: +44 (0) 7785 703 523 Office: +44 (0) 121 309 0099 |
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture, marketing, and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
Forward Looking Statement
This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.